EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enzyme‐Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors

Yuhui Zhang, Li Wang, Leo Corcilius, Amal K Reji iD, Richard J Payne, Bin Hong, Thomas Durek iD, Conan K Wang iD, David J Craik iD

ChemBioChem · 14.04.2026 · 27 (7)

DOI: 10.1002/cbic.202500972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 08.04.2026. Verfasst von Yuhui Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Peptides, Enzyme Inhibitors. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian Research Council, NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well‐established target for lowering cholesterol and is abundantly present in the extracellular space. Inhibitors of PCSK9 have achieved marked success in the clinic, but an alternative strategy for therapeutic modulation is emerging through the degradation of PCSK9. This novel strategy has been enabled by the identification of cell surface receptors such as the asialoglycoprotein receptor (ASGPR), which mediates the lysosomal degradation of extracellular ligands. Given the importance of this therapeutic mechanism, we investigated the synthesis of bifunctional molecules comprising Tri‐GalNAc (an ASGPR binder) with a peptide inhibitor we previously reported. In addition to chemical synthesis, we report a novel method for the production of Tri‐GalNAc‐conjugated peptides, involving the use of enzymatically mediated ligation postsynthesis. We demonstrate that both the synthetic constructs and chemoenzymatic constructs have the intended structures and in vitro activities. While these molecules did not show cellular activities, the chemical and biochemical methods reported here could be broadly applied to the construction of LYTACs in general. One significant challenge that this work overcomes is the C‐terminal attachment of Tri‐GalNAc, which remains hitherto a difficult experimental task for not only peptides but also larger biologics in particular.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsPeptidesEnzyme InhibitorsHumansProprotein Convertase 9

Stichwörter der Autor:innen

LYTACdrug designhypercholesterolemiapeptide

Substanzen

PCSK9 InhibitorsProprotein Convertase 9PCSK9 protein, humanPeptidesEnzyme Inhibitors

Autor:innen und Institutionen

  • Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
  • School of Chemistry, The University of Sydney, Sydney, Australia.

ORCID-Profile: Amal K Reji, Thomas Durek, Conan K Wang, David J Craik

Förderung

  • National Health and Medical Research Council
  • Australian Research Council
  • NHMRC

Zitieren

APA

Zhang, Y., Wang, L., Corcilius, L., Reji, A. K., Payne, R. J., Hong, B., Durek, T., Wang, C. K., & Craik, D. J. (2026). Enzyme‐Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. ChemBioChem, 27(7). https://doi.org/10.1002/cbic.202500972

Vancouver

Zhang Y, Wang L, Corcilius L, Reji AK, Payne RJ, Hong B, et al. Enzyme‐Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. ChemBioChem. 2026;27(7). doi:10.1002/cbic.202500972

BibTeX
@article{Zhang2026,
  author = {Zhang, Yuhui and Wang, Li and Corcilius, Leo and Reji, Amal K and Payne, Richard J and Hong, Bin and Durek, Thomas and Wang, Conan K and Craik, David J},
  title = {Enzyme‐Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors},
  journal = {ChemBioChem},
  year = {2026},
  volume = {27},
  number = {7},
  doi = {10.1002/cbic.202500972}
}
Kostenlos starten →